AUSSENDER
AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Ansprechpartner:
AOP
Tel.: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
Schlagwörter:
  • AOP Orphan

  • ASH

  • PharmaEssentia Corporation

  • Polycythemia Vera

  • ropeginterferon
WETTER
Graz: Regen
Innsbruck: Regenschauer
Linz: bedeckt
Wien: bedeckt
11°
© wetter.net

Stadtname / PLZ
AKTIENKURSE
 
Pressefach
Fr, 24.02.2017
AOP Orphan Pharmaceuticals Aktiengesellschaft  (5 Meldungen)
AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016. * At 12 months of treatment ropeginterferon alfa-2b showed non-inferio(...)
AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in PV
2016-12-05, pts20161205006 Forschung/Technologie, Medizin/Wellness
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
2016-07-11, pts20160711014 Medizin/Wellness, Produkte/Innovationen
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
2016-07-11, pts20160711013 Medizin/Wellness, Produkte/Innovationen
Roland Bindeus wechselt von Baxalta zu AOP Orphan
2016-04-05, pts20160405030 Medizin/Wellness, Bildung/Karriere